002393 力生制药
已收盘 11-22 15:00:00
资讯
新帖
简况
力生制药(002393.SZ)：化学原料药精氨酸培哚普利通过上市申请
智通财经 · 11-22 15:49
力生制药(002393.SZ)：化学原料药精氨酸培哚普利通过上市申请
力生制药获得实用新型专利授权：“一种便于上料的高速自动理瓶机”
证券之星 · 11-16
力生制药获得实用新型专利授权：“一种便于上料的高速自动理瓶机”
天津发展：力生制药前三季度归母净利润1.69亿元 同比下降50.6%
新浪港股 · 10-30
天津发展：力生制药前三季度归母净利润1.69亿元 同比下降50.6%
天津发展(00882)：力生制药前三季度归母净利润1.69亿元，同比下降50.6%
智通财经 · 10-30
天津发展(00882)：力生制药前三季度归母净利润1.69亿元，同比下降50.6%
图解力生制药三季报：第三季度单季净利润同比减73.50%
证券之星 · 10-30
图解力生制药三季报：第三季度单季净利润同比减73.50%
力生制药(002393.SZ)发布前三季度业绩，净利润1.69亿元，同比下降50.61%
智通财经 · 10-29
力生制药(002393.SZ)发布前三季度业绩，净利润1.69亿元，同比下降50.61%
力生制药最新公告：化学原料药阿普米司特通过上市许可申请
证券之星 · 10-17
力生制药最新公告：化学原料药阿普米司特通过上市许可申请
力生制药(002393.SZ)：化学原料药阿普米司特通过上市许可申请
智通财经 · 10-17
力生制药(002393.SZ)：化学原料药阿普米司特通过上市许可申请
力生制药：化学原料药阿普米司特通过上市许可申请
美港电讯 · 10-17
力生制药：化学原料药阿普米司特通过上市许可申请
天津发展附属力生制药认购本金金额2.1亿元结构性存款
智通财经 · 09-26
天津发展附属力生制药认购本金金额2.1亿元结构性存款
天津发展(00882)附属力生制药认购本金金额2.1亿元结构性存款
智通财经 · 09-26
天津发展(00882)附属力生制药认购本金金额2.1亿元结构性存款
中邮证券：给予力生制药买入评级
证券之星 · 09-04
中邮证券：给予力生制药买入评级
力生制药（002393）8月26日主力资金净卖出151.14万元
证券之星 · 08-27
力生制药（002393）8月26日主力资金净卖出151.14万元
力生制药（002393）2024年中报简析：营收净利润同比双双增长
证券之星 · 08-24
力生制药（002393）2024年中报简析：营收净利润同比双双增长
力生制药(002393)6月30日股东户数1.79万户，较上期减少4.33%
证券之星 · 08-23
力生制药(002393)6月30日股东户数1.79万户，较上期减少4.33%
开源证券：给予力生制药买入评级
证券之星 · 08-23
开源证券：给予力生制药买入评级
天津发展：力生制药中期实现归母净利润1.02亿元，同比增长13.5%
智通财经 · 08-23
天津发展：力生制药中期实现归母净利润1.02亿元，同比增长13.5%
天津发展(00882)：力生制药中期实现归母净利润1.02亿元，同比增长13.5%
智通财经 · 08-23
天津发展(00882)：力生制药中期实现归母净利润1.02亿元，同比增长13.5%
图解力生制药中报：第二季度单季净利润同比减1.11%
证券之星 · 08-23
图解力生制药中报：第二季度单季净利润同比减1.11%
力生制药(002393.SZ)：盐酸普萘洛尔原料药通过上市申请
智通财经 · 08-22
力生制药(002393.SZ)：盐酸普萘洛尔原料药通过上市申请
加载更多
公司概况
公司名称：
天津力生制药股份有限公司
所属行业：
医药制造业
上市日期：
2010-04-23
主营业务：
天津力生制药股份有限公司主营业务为医药产品研发、生产和销售。公司主要产品有主胶囊、片剂、针剂等。
发行价格：
45.00
{"stockData":{"symbol":"002393","market":"SZ","secType":"STK","nameCN":"力生制药","latestPrice":17.81,"timestamp":1732259031000,"preClose":18.65,"halted":0,"volume":6021938,"delay":0,"floatShares":254999999,"shares":258000000,"eps":0.7305,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.84,"latestTime":"11-22 15:00:00","open":18.64,"high":18.86,"low":17.81,"amount":110000000,"amplitude":0.0563,"askPrice":17.83,"askSize":74,"bidPrice":17.81,"bidSize":54,"shortable":0,"etf":0,"ttmEps":0.7305,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732498200000},"adr":0,"adjPreClose":18.65,"symbolType":"stock","openAndCloseTimeList":[[1732239000000,1732246200000],[1732251600000,1732258800000]],"highLimit":20.52,"lowLimit":16.79,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":257942988,"pbRate":0.97,"roa":"--","roe":"3.43%","epsLYR":1.97,"committee":-0.403055,"marketValue":4594000000,"floatMarketCap":4549000000,"peRate":24.380562,"changeRate":-0.045,"turnoverRate":0.0236,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2024-11-25。"},"requestUrl":"/m/hq/s/002393","defaultTab":"news","newsList":[{"id":"2485328775","title":"力生制药(002393.SZ)：化学原料药精氨酸培哚普利通过上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2485328775","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485328775?lang=zh_cn&edition=full","pubTime":"2024-11-22 15:49","pubTimestamp":1732261795,"startTime":"0","endTime":"0","summary":"智通财经APP讯，力生制药(002393.SZ)公告，公司收到国家药品监督管理局颁发的关于精氨酸培哚普利原料药《化学原料药上市申请批准通知书》，该品种通过化学原料药上市申请。精氨酸培哚普利为血管扩张药，常用剂型为片剂，用于高血压与充血性心力衰竭。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1214539.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0028","BK0239","002393"],"gpt_icon":0},{"id":"2483558237","title":"力生制药获得实用新型专利授权：“一种便于上料的高速自动理瓶机”","url":"https://stock-news.laohu8.com/highlight/detail?id=2483558237","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483558237?lang=zh_cn&edition=full","pubTime":"2024-11-16 03:41","pubTimestamp":1731699686,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示力生制药新获得一项实用新型专利授权，专利名为“一种便于上料的高速自动理瓶机”，专利申请号为CN202420031569.3，授权日为2024年11月15日。今年以来力生制药新获得专利授权3个，较去年同期减少了66.67%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111600009229.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","002393","BK0028"],"gpt_icon":0},{"id":"2479267364","title":"天津发展：力生制药前三季度归母净利润1.69亿元 同比下降50.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479267364","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479267364?lang=zh_cn&edition=full","pubTime":"2024-10-30 07:27","pubTimestamp":1730244420,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n 天津发展（00882）发布公告，公司间接非全资附属公司力生制药截至2024年9月30日止九个月实现营业总收入10.24亿元（人民币，下同），同比增长12.3%；归属于母公司所有者的净利润1.69亿元，同比下降50.6%；基本每股收益0.66元。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-10-30/doc-incuhrze1330543.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-10-30/doc-incuhrze1330543.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["00882","002393"],"gpt_icon":0},{"id":"2479726989","title":"天津发展(00882)：力生制药前三季度归母净利润1.69亿元，同比下降50.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479726989","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479726989?lang=zh_cn&edition=full","pubTime":"2024-10-30 06:12","pubTimestamp":1730239973,"startTime":"0","endTime":"0","summary":"智通财经APP讯，天津发展(00882)发布公告，公司间接非全资附属公司力生制药截至2024年9月30日止九个月实现营业总收入10.24亿元(人民币，下同)，同比增长12.3%;归属于母公司所有者的净利润1.69亿元，同比下降50.6%;基本每股收益0.66元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1203274.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00882","002393"],"gpt_icon":0},{"id":"2479423495","title":"图解力生制药三季报：第三季度单季净利润同比减73.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479423495","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479423495?lang=zh_cn&edition=full","pubTime":"2024-10-30 01:19","pubTimestamp":1730222358,"startTime":"0","endTime":"0","summary":"证券之星消息，力生制药2024年三季报显示，公司主营收入10.24亿元，同比上升12.31%；归母净利润1.69亿元，同比下降50.61%；扣非净利润1.06亿元，同比下降22.5%；其中2024年第三季度，公司单季度主营收入2.79亿元，同比上升9.86%；单季度归母净利润6689.81万元，同比下降73.5%；单季度扣非净利润712.77万元，同比下降85.27%；负债率16.85%，投资收益7680.71万元，财务费用-4066.2万元，毛利率55.21%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103000000717.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002393"],"gpt_icon":0},{"id":"2479880092","title":"力生制药(002393.SZ)发布前三季度业绩，净利润1.69亿元，同比下降50.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479880092","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479880092?lang=zh_cn&edition=full","pubTime":"2024-10-29 21:48","pubTimestamp":1730209685,"startTime":"0","endTime":"0","summary":"智通财经APP讯，力生制药(002393.SZ)发布2024年三季度报告，前三季度，公司实现营业收入10.24亿元，同比增长12.31%。归属于上市公司股东的净利润1.69亿元，同比下降50.61%。归属于上市公司股东的扣除非经常性损益的净利润1.06亿元，同比下降22.50%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1202963.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002393"],"gpt_icon":0},{"id":"2476819441","title":"力生制药最新公告：化学原料药阿普米司特通过上市许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2476819441","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476819441?lang=zh_cn&edition=full","pubTime":"2024-10-17 16:12","pubTimestamp":1729152748,"startTime":"0","endTime":"0","summary":"力生制药公告，近日，公司收到国家药监局颁发的阿普米司特原料药《化学原料药上市申请批准通知书》，该原料药通过境内生产化学原料药上市申请。该原料药临床上用于治疗符合接受光疗或系统治疗指征的中度至重度斑块状银屑病的成人患者。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024101700023879.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","002393","BK0239"],"gpt_icon":0},{"id":"2476195058","title":"力生制药(002393.SZ)：化学原料药阿普米司特通过上市许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2476195058","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476195058?lang=zh_cn&edition=full","pubTime":"2024-10-17 15:48","pubTimestamp":1729151295,"startTime":"0","endTime":"0","summary":"智通财经APP讯，力生制药(002393.SZ)发布公告，近日，公司收到国家药品监督管理局颁发的阿普米司特原料药(以下简称“该原料药”)《化学原料药上市申请批准通知书》(通知书编号：2024YS00982)，该原料药通过境内生产化学原料药上市申请。该品种主要是通过抑制磷酸二酯酶4的合成，增加细胞内环磷酸腺苷的含量，从而起到抑制炎症的作用。临床上用于治疗符合接受光疗或系统治疗指征的中度至重度斑块状银屑病的成人患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1195270.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002393","BK0239","BK0028","BK0188"],"gpt_icon":0},{"id":"2476195273","title":"力生制药：化学原料药阿普米司特通过上市许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2476195273","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476195273?lang=zh_cn&edition=full","pubTime":"2024-10-17 15:46","pubTimestamp":1729151162,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["002393","BK0028","BK0188","BK0239"],"gpt_icon":0},{"id":"2470731894","title":"天津发展附属力生制药认购本金金额2.1亿元结构性存款","url":"https://stock-news.laohu8.com/highlight/detail?id=2470731894","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470731894?lang=zh_cn&edition=full","pubTime":"2024-09-26 21:00","pubTimestamp":1727355603,"startTime":"0","endTime":"0","summary":"天津发展(00882)发布公告，于2024年9月26日，公司间接非全资附属公司力生制药与渤海银行订立第三份渤海银行理财协议，以本金金额人民币 2.1亿元(相当于约港币2.31亿元)认购另一笔结构性存款 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20240926/c662024832.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["002393","BK0239","BK0188","BK0028"],"gpt_icon":0},{"id":"2470738536","title":"天津发展(00882)附属力生制药认购本金金额2.1亿元结构性存款","url":"https://stock-news.laohu8.com/highlight/detail?id=2470738536","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470738536?lang=zh_cn&edition=full","pubTime":"2024-09-26 20:16","pubTimestamp":1727353010,"startTime":"0","endTime":"0","summary":"智通财经APP讯，天津发展(00882)发布公告，于2024年9月26日，公司间接非全资附属公司力生制药与渤海银行订立第三份渤海银行理财协议，以本金金额人民币 2.1亿元(相当于约港币2.31亿元)认购另一笔结构性存款。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1187778.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1232","BK0239","BK0188","002393","00882","BK0028"],"gpt_icon":0},{"id":"2464034849","title":"中邮证券：给予力生制药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2464034849","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464034849?lang=zh_cn&edition=full","pubTime":"2024-09-04 14:30","pubTimestamp":1725431441,"startTime":"0","endTime":"0","summary":"中邮证券有限责任公司蔡明子,古意涵近期对力生制药进行研究并发布了研究报告《2024H1增长稳健，存量盘活增量培育成效明显》，本报告对力生制药给出买入评级，当前股价为15.14元。费率方面，2024H1期间费用合计下降6.9pct。二是盘活品牌资产，“三鱼”牌入选第三批中华老字号，完成力生制药45个产品“三鱼”商标替换工作，提升品牌影响力；积极推动“三鱼”商标申请驰名商标。该股最近90天内共有1家机构给出评级，买入评级1家。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024090400019266.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","002393"],"gpt_icon":0},{"id":"2462090352","title":"力生制药（002393）8月26日主力资金净卖出151.14万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2462090352","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462090352?lang=zh_cn&edition=full","pubTime":"2024-08-27 09:24","pubTimestamp":1724721862,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年8月26日收盘，力生制药报收于15.28元，下跌1.48%，换手率0.83%，成交量2.13万手，成交额3251.02万元。近5日资金流向一览见下表：力生制药融资融券信息显示，融资方面，当日融资买入230.88万元，融资偿还82.41万元，融资净买入148.47万元。力生制药主营业务：从事医药产品研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082700008319.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0239","002393"],"gpt_icon":0},{"id":"2461758524","title":"力生制药（002393）2024年中报简析：营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2461758524","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461758524?lang=zh_cn&edition=full","pubTime":"2024-08-24 06:12","pubTimestamp":1724451162,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期力生制药发布2024年中报。根据财报显示，力生制药营收净利润同比双双增长。截至本报告期末，公司营业总收入7.45亿元，同比上升13.25%，归母净利润1.02亿元，同比上升13.5%。按单季度数据看，第二季度营业总收入3.8亿元，同比上升17.99%，第二季度归母净利润4319.87万元，同比下降1.11%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082400005673.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002393"],"gpt_icon":0},{"id":"2461455246","title":"力生制药(002393)6月30日股东户数1.79万户，较上期减少4.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2461455246","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461455246?lang=zh_cn&edition=full","pubTime":"2024-08-23 17:05","pubTimestamp":1724403941,"startTime":"0","endTime":"0","summary":"证券之星消息，近日力生制药披露，截至2024年6月30日公司股东户数为1.79万户，较4月10日减少812.0户，减幅为4.33%。在化学制药行业个股中，力生制药股东户数低于行业平均水平，截至6月30日，化学制药行业平均股东户数为3.23万户。从股价来看，2024年4月10日至2024年6月30日，力生制药区间跌幅为7.84%，在此期间股东户数减少812.0户，减幅为4.33%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082300031403.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002393","BK0188","BK0239","BK0028"],"gpt_icon":0},{"id":"2461511255","title":"开源证券：给予力生制药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2461511255","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461511255?lang=zh_cn&edition=full","pubTime":"2024-08-23 16:32","pubTimestamp":1724401929,"startTime":"0","endTime":"0","summary":"开源证券股份有限公司余汝意近期对力生制药进行研究并发布了研究报告《公司信息更新报告：业绩稳健增长，进一步夯实科改示范企业地位》，本报告对力生制药给出买入评级，当前股价为15.51元。 力生制药 业绩稳健增长，销售费用率有所下降，维持“买入”评级 2024H1公司实现营业收入7.45亿元；归母净利润1.02亿元；扣非归母净利润0.99亿元。该股最近90天内共有1家机构给出评级，买入评级1家。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082300028381.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","002393"],"gpt_icon":0},{"id":"2461086893","title":"天津发展：力生制药中期实现归母净利润1.02亿元，同比增长13.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2461086893","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461086893?lang=zh_cn&edition=full","pubTime":"2024-08-23 07:20","pubTimestamp":1724368845,"startTime":"0","endTime":"0","summary":"天津发展(00882)发布其间接非全资附属天津力生制药股份有限公司截至2024年6月30日止6个月中期业绩，营业总收入7.45亿元，同比增长13.25%;归属于母公司所有者的净利润1.02亿元，同比增长13.5 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/20240823/c661062182.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["002393"],"gpt_icon":0},{"id":"2461308870","title":"天津发展(00882)：力生制药中期实现归母净利润1.02亿元，同比增长13.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2461308870","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461308870?lang=zh_cn&edition=full","pubTime":"2024-08-23 07:00","pubTimestamp":1724367603,"startTime":"0","endTime":"0","summary":"智通财经APP讯，天津发展(00882)发布其间接非全资附属天津力生制药股份有限公司截至2024年6月30日止6个月中期业绩，营业总收入7.45亿元，同比增长13.25%;归属于母公司所有者的净利润1.02亿元，同比增长13.5%;基本每股收益0.4元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1169031.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002393","00882"],"gpt_icon":0},{"id":"2461771325","title":"图解力生制药中报：第二季度单季净利润同比减1.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2461771325","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461771325?lang=zh_cn&edition=full","pubTime":"2024-08-23 01:29","pubTimestamp":1724347759,"startTime":"0","endTime":"0","summary":"证券之星消息，力生制药2024年中报显示，公司主营收入7.45亿元，同比上升13.25%；归母净利润1.02亿元，同比上升13.5%；扣非净利润9917.93万元，同比上升11.72%；其中2024年第二季度，公司单季度主营收入3.8亿元，同比上升17.99%；单季度归母净利润4319.87万元，同比下降1.11%；单季度扣非净利润4030.57万元，同比下降7.09%；负债率18.46%，投资收益301.75万元，财务费用-3711.68万元，毛利率56.16%。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082300001923.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002393"],"gpt_icon":0},{"id":"2461390626","title":"力生制药(002393.SZ)：盐酸普萘洛尔原料药通过上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2461390626","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461390626?lang=zh_cn&edition=full","pubTime":"2024-08-22 19:13","pubTimestamp":1724325190,"startTime":"0","endTime":"0","summary":"智通财经APP讯，力生制药(002393.SZ)发布公告，近日，公司收到国家药品监督管理局颁发的关于盐酸普萘洛尔原料药《化学原料药上市申请批准通知书》(通知书编号：2024YS00838)，该品种通过化学原料药上市申请。据悉，普萘洛尔是非选择性β-肾上腺素受体阻滞剂，可竞争性结合肾上腺素受体的β1和β2两种亚型，减慢心率，抑制心脏收缩力与传导、减少循环血量、降低心肌耗氧量。临床主要用于治疗多种原因所致的心律失常，也可用于心绞痛，高血压嗜铬细胞瘤(手术前准备)等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1168683.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0028","BK0188","002393"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2010-04-23","address":"天津市西青区西青经济技术开发区赛达北一道16号","stockEarnings":[{"period":"1week","weight":0.0427},{"period":"1month","weight":0.0253},{"period":"3month","weight":0.1483},{"period":"6month","weight":-0.0022},{"period":"1year","weight":-0.0647},{"period":"ytd","weight":-0.0218}],"companyName":"天津力生制药股份有限公司","boardCode":"AI0027","perCapita":"13687股","boardName":"医药制造业","registeredCapital":"25794万元","compareEarnings":[{"period":"1week","weight":-0.0191},{"period":"1month","weight":-0.0108},{"period":"3month","weight":0.1446},{"period":"6month","weight":0.0577},{"period":"1year","weight":0.0671},{"period":"ytd","weight":0.0982}],"survey":" 天津力生制药股份有限公司主营业务为医药产品研发、生产和销售。公司主要产品有主胶囊、片剂、针剂等。","serverTime":1732301273114,"listedPrice":45,"stockholders":"18662人(较上一季度增加8.48%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"力生制药(002393)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供力生制药(002393)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"力生制药,002393,力生制药股票,力生制药股票老虎,力生制药股票老虎国际,力生制药行情,力生制药股票行情,力生制药股价,力生制药股市,力生制药股票价格,力生制药股票交易,力生制药股票购买,力生制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"力生制药(002393)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供力生制药(002393)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}